Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors

NCT06849921 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06849921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06849921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Precise Design of Cell Therapy for Relapsed and Refractory Hematological Tumors
Lead sponsor
Ruijin Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
November 7, 2024
Completion date
December 30, 2030
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic disease, precise design of cell therapy for relapsed and refractory hematological tumors